Search hospitals > Iowa > Iowa City
University of Iowa Hospitals and Clinics
Claim this profileIowa City, Iowa 52242
Global Leader in Cancer
Global Leader in High Blood Pressure
Conducts research for Tumors
Conducts research for Lymphoma
Conducts research for Leukemia
982 reported clinical trials
164 medical researchers
Summary
University of Iowa Hospitals and Clinics is a medical facility located in Iowa City, Iowa. This center is recognized for care of Cancer, High Blood Pressure, Tumors, Lymphoma, Leukemia and other specialties. University of Iowa Hospitals and Clinics is involved with conducting 982 clinical trials across 1,492 conditions. There are 164 research doctors associated with this hospital, such as David S. Dickens, Mariko Sato, Muhammad Furqan, and Yousef Zakharia, MD.Area of expertise
1Cancer
Global LeaderStage IV
Stage III
FGFR3
2High Blood Pressure
Global LeaderTop PIs
David S. DickensUniversity of Iowa/Holden Comprehensive Cancer Center9 years of reported clinical research
Expert in Brain Tumor
Expert in Tumors
63 reported clinical trials
121 drugs studied
Mariko SatoUniversity of Iowa/Holden Comprehensive Cancer Center7 years of reported clinical research
Expert in Brain Tumor
Expert in Tumors
49 reported clinical trials
95 drugs studied
Muhammad FurqanUniversity of Iowa Healthcare Cancer Services Quad Cities5 years of reported clinical research
Expert in Lung Cancer
Expert in Non-Small Cell Lung Cancer
20 reported clinical trials
35 drugs studied
Yousef Zakharia, MDUniversity of Iowa Hospitals and Clinics2 years of reported clinical research
Studies Cancer
Studies Renal Cell Carcinoma
19 reported clinical trials
45 drugs studied
Clinical Trials running at University of Iowa Hospitals and Clinics
Breast Cancer
Multiple Myeloma
Melanoma
Emphysema
Plasma Cell Neoplasms
Chronic Kidney Disease
Liver Failure
Osteoarthritis
High Blood Pressure
Patent Ductus Arteriosus
Sacituzumab Govitecan
for Triple-Negative Breast Cancer
This trial is testing a drug called sacituzumab govitecan-hziy, which targets and kills cancer cells. It focuses on patients with advanced triple-negative breast cancer who have limited treatment options. The drug works by attaching to cancer cells and releasing a substance that kills them. Sacituzumab govitecan-hziy is an FDA-approved treatment for metastatic triple-negative breast cancer, especially for patients who have already tried other treatments.
Recruiting4 awards Phase 3
Giredestrant + Hormone Therapy
for Early-Stage Breast Cancer
This trial is testing giredestrant, a medication given after initial treatment to prevent breast cancer from returning. It focuses on patients with a specific type of early-stage breast cancer that is hormone-driven and at higher risk of recurrence. Giredestrant works by blocking the hormone estrogen from helping cancer cells grow. Giredestrant has shown promise in previous studies.
Recruiting2 awards Phase 311 criteria
PF-07220060 + Fulvestrant
for Advanced Breast Cancer
The purpose of this study is to learn about the safety and how effective the study medicine (PF-07220060) plus fulvestrant is compared to the study doctor's choice of treatment in people with advanced or metastatic breast cancer. Advanced cancer is the one that is unlikely to be cured or taken care of with treatment. Metastatic cancer is the one that has spread to other parts of the body. This study is seeking female and male participants who: * are 18 years of age or older; * are hormone receptor (HR)-positive and human epidermal growth factor receptor 2 (HER2)-negative; * have advanced or metastatic breast cancer after taking other treatments before this study; * have not taken or need to take medications that are not allowed by the study protocol; * do not have any medical or mental conditions that may increase the risk of study participation. Half of the participants will take PF-07220060 two times daily by mouth along with fulvestrant. Fulvestrant will be given as a shot into the muscle. The other half will take the study doctor's choice of treatment which can either be: * Fulvestrant alone taken as shot into the muscle. * Everolimus along with exemestane taken once daily by mouth. This study will compare the experiences of participants receiving the study medicine plus fulvestrant to those who are receiving the study doctor's choice of treatment. This will help decide if the study medicine is safe and effective. Participants will receive study treatment and/or will be in the study until: * imaging scans (such as an MRI and/or CT) show that their cancer is getting worse. * the study doctor thinks the participant is no longer benefitting from the study medicine. * has side effects that become too severe. A side effect is a reaction (expected or unexpected) to a medicine or treatment you take. * the participant chooses to stop taking part.
Recruiting2 awards Phase 3
Similar Hospitals nearby
Select from list below to view details
Frequently asked questions
What kind of research happens at University of Iowa Hospitals and Clinics?
University of Iowa Hospitals and Clinics is a medical facility located in Iowa City, Iowa. This center is recognized for care of Cancer, High Blood Pressure, Tumors, Lymphoma, Leukemia and other specialties. University of Iowa Hospitals and Clinics is involved with conducting 982 clinical trials across 1,492 conditions. There are 164 research doctors associated with this hospital, such as David S. Dickens, Mariko Sato, Muhammad Furqan, and Yousef Zakharia, MD.
Where is University of Iowa Hospitals and Clinics located?
To reach the University of Iowa Hospitals and Clinics: Take Interstate 80 East to exit 239A (Highway 218), follow Highway 218 South for 3 miles to exit 93 (Melrose Avenue), turn left onto Melrose Avenue and continue for 2.4 miles to Hawkins Drive, turn left and the hospital is immediately on the right. For detailed directions, consider viewing a printable map of the hospital's main entrances, parking ramps, and campus layout.
Who should I call to ask about financial aid or insurance network?
The University of Iowa Hospitals and Clinics offers comprehensive financial counseling services, including assistance with billing, insurance, and financial aid based on income guidelines. For payment arrangements, financial assistance, or insurance updates, contact them at 1-319-384-2196. Employees seeking financial well-being resources can reach out to Horizons at financialwellnesscenter@horizonsfamily.org or 319-398-3943.
What insurance does University of Iowa Hospitals and Clinics accept?
The University of Iowa Hospitals and Clinics accepts a variety of insurance plans, such as UIChoice and UISelect for employees, Medicare, and Social Security for retirees, alongside a broad spectrum of commercial insurance plans for in-network and out-of-network coverage. For confirmation on whether a specific insurance plan is accepted, please contact the insurance provider directly or consult the UI Health Care Insurance Contract List.
What awards or recognition has University of Iowa Hospitals and Clinics received?
The University of Iowa Hospitals and Clinics, located in Iowa City, Iowa, is the state's top-ranked hospital, boasting national rankings in multiple medical specialties. It is a hub for research and innovation, with over 250 laboratories receiving more than $200 million in external funding annually. The hospital's nursing staff is deeply involved in both independent and collaborative research, engaging in projects with global partners.